menu

How to Talk About Pneumococcal Disease With Your Adult Patients at Increased Risk

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
x
Hello, there.

Indications and Usage 

PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

Select Safety Information for PNEUMOVAX 23

Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.

Read full SSI for PNEUMOVAX 23>>
CONTINUE TO PROGRAM

How to Talk About Pneumococcal Disease With Your Adult Patients at Increased Risk

How to Talk About Pneumococcal Disease With Your Adult Patients at Increased Risk
RestartResume

How can you maximize your time and prioritize vaccination with your patients under age 65 who are at increased risk of pneumococcal disease? 

Take Post-Survey

If you’ve already completed the activity.

  • Overview

    The time to discuss preventative care with your patients under age 65 who are at increased risk of pneumococcal disease1,a can be limited,2,3 but there are ways you can make a positive impact by considering 4 key steps.4 Here to give us a closer look at how we can carry out these steps is Dr. Vincent Hsu, an infectious disease specialist. 

    References

    1. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum lnfect Dis. 2014;1(1)1–9.
    2. Wagholikar KB, Hankey RA, Decker LK, et al. Evaluation of the effect of decision support on the efficiency of primary care providers in the outpatient practice. J Prim Care Community Health. 2015;6(1):54-60.
    3. National Foundation for Infectious Diseases. Call to action: preventing pneumococcal disease in US adults with chronic conditions. Available https://www.nfid.org/wp-content/uploads/2019/08/cta-chronic-conditions.pdf Accessed August 9, 2020
    4. Centers for Disease Control and Prevention (CDC). Standards for adult immunization practice: overview. cdc.gov/vaccines/hcp/adults/for-practice/standards/index.html. Reviewed May 2, 2016. Accessed July 20, 2020.

    aStudy Design: Retrospective cohort study (adults aged-matched 18–64 years) using data from January 1, 2006, through December 31, 2010, from 3 health care claims databases representing >35 million insured adults. Risk for IPD was compared to age matched healthy counterparts.1

    Indications and Usage 

    PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

    PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

    PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

    Select Safety Information for PNEUMOVAX 23

    Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.

    Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

    Use caution and appropriate care in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.

    Available human data from clinical trials of PNEUMOVAX 23 in pregnancy have not established the presence or absence of a vaccine-associated risk.

    Persons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to PNEUMOVAX 23.

    PNEUMOVAX 23 may not be effective in preventing pneumococcal meningitis in patients who have chronic cerebrospinal fluid (CSF) leakage resulting from congenital lesions, skull fractures, or neurosurgical procedures.

    The most common adverse reactions, reported in >10% of subjects vaccinated with PNEUMOVAX 23 in clinical trials, were: injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia.

    Vaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal infection.

    Before administering PNEUMOVAX 23, please read the accompanying Prescribing Information. The Patient Information also is available.

Programs 10/22/20